Business Context and Reporting Period
This Form 8-K filing by MEI Pharma, Inc. (trading symbol: MEIP) reports corporate governance changes effective May 3, 2021. The report date is April 30, 2021. The filing addresses the departure of the Chief Medical Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial disclosure relates to executive compensation for the newly appointed officer.
- New Officer Annual Salary: $463,000
- Stock Option Grant: 75,000 shares of common stock
- Vesting Schedule: 25% on the first anniversary; remaining 75% monthly over three years.
Material Changes
The primary material change is the leadership transition within the medical department:
- Departure: Robert Mass, Chief Medical Officer, is retiring effective May 3, 2021. He will continue to serve as a strategic advisor.
- Appointment: Richard Ghalie is appointed as Chief Medical Officer effective May 3, 2021.
Management Commentary and Risks
Management highlights Dr. Ghalie's extensive background, including over 25 years of drug development experience, a medical degree from the French School of Medicine in Lebanon, and an MBA from the University of Washington. He has led teams resulting in the approval of four new indications. The filing explicitly states there are no related party transactions, family relationships with other directors/officers, or undisclosed material plans involving Dr. Ghalie.
Investor Verification Checklist
- Verify the effective date of the leadership transition (May 3, 2021).
- Confirm the vesting terms of the 75,000 stock options granted to Dr. Ghalie.
- Review the attached press release (Exhibit 99.1) for additional strategic context regarding the retirement and appointment.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.